Jean-Pierre Valentin
Research Subjects
Jean-Pierre Valentin has a total of 274 co-authors. Here are the top co-authors by number of shared publications:
- Annie Delaunois
UCB Biopharma SRL , 1420 Braine-l’Alleud
6 shared publications - Derek J. Leishman
Eli Lilly and Company, Indianapolis, USA
5 shared publications Duncan Armstrong
Novartis Biomedical Research, Cambridge, USA
5 shared publicationsMarie-Luce Rosseels
UCB Biopharma SRL , 1420 Braine-l’Alleud
5 shared publications- Friedemann Schmidt
Sanofi, Frankfurt, Germany
4 shared publications - Hugo M. Vargas
Translational Safety & Bioanalytical Sciences Amgen Research Thousand Oaks California USA
4 shared publications
Latest Publications
- Open Access
- 2 October 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (5) , 1240-1249
Pediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report
Pediatric developmental safety assessment presents distinct challenges in drug development. Children undergo dynamic changes in organ systems and drug disposition pathways during development, and drug‐related effects may be delayed or manifested differently than in adults. Pharmacovigilance data, primarily from adults, is not always predictive of the response in children. Historically, juvenile animal studies have been used for nonclinical pediatric drug safety assessments exclusively, but the reduction in animal testing is a goal of public health agencies. To address this concern, the Office of Clinical Pharmacology at the U.S. FDA and the Triangle CERSI (Center of Excellence in Regulatory Science and Innovation) convened a workshop entitled: “Pediatric Developmental Safety Assessment and New Approach Methodologies (NAMs),” attended by experts from regulatory agencies, academia, and industry. Discussions focused on three overarching topics: (i) Secondary Pharmacology Screening Tools for Assessing Pediatric Developmental Safety; (ii) Non‐clinical Tools for Pediatric Developmental Safety Assessment; and (iii) Computational and Data‐Driven Tools for Pediatric Developmental Safety. These topics were examined within the framework of the S11 Nonclinical Safety Testing In Support of Development of Pediatric Pharmaceuticals and E11A Pediatric Extrapolation guidances, which promote structured, question‐based pediatric extrapolation in drug development and authorization. The workshop concluded that NAMs hold considerable promise to advance the assessment of pediatric drug developmental safety.
- 2 October 2026
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 120 (5) , 1240-1249
Open AccessPediatric Developmental Safety Assessment and New Approach Methodologies: US FDA/Triangle CERSI Workshop Report
Pediatric developmental safety assessment presents distinct challenges in drug development. Children undergo dynamic changes in organ systems and drug disposition pathways during development, and drug‐related effects may be delayed or manifested differently than in adults. Pharmacovigilance data, primarily from adults, is not always predictive of the response in children. Historically, juvenile animal studies have been used for nonclinical pediatric drug safety assessments exclusively, but the reduction in animal testing is a goal of public health agencies. To address this concern, the Office of Clinical Pharmacology at the U.S. FDA and the Triangle CERSI (Center of Excellence in Regulatory Science and Innovation) convened a workshop entitled: “Pediatric Developmental Safety Assessment and New Approach Methodologies (NAMs),” attended by experts from regulatory agencies, academia, and industry. Discussions focused on three overarching topics: (i) Secondary Pharmacology Screening Tools for Assessing Pediatric Developmental Safety; (ii) Non‐clinical Tools for Pediatric Developmental Safety Assessment; and (iii) Computational and Data‐Driven Tools for Pediatric Developmental Safety. These topics were examined within the framework of the S11 Nonclinical Safety Testing In Support of Development of Pediatric Pharmaceuticals and E11A Pediatric Extrapolation guidances, which promote structured, question‐based pediatric extrapolation in drug development and authorization. The workshop concluded that NAMs hold considerable promise to advance the assessment of pediatric drug developmental safety.
- 4 July 2026
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 171, 106173
Cardiovascular toxicity as a globally harmonized system hazard trait: The evidence and the path forward
- 4 July 2026
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 171, 106173
Cardiovascular toxicity as a globally harmonized system hazard trait: The evidence and the path forward
- 22 April 2025
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 24 (6) , 482-484
Shaping secondary pharmacology panels of the future: evolving target selection criteria for safety panels
- 22 April 2025
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 24 (6) , 482-484
Shaping secondary pharmacology panels of the future: evolving target selection criteria for safety panels
- 6 March 2025
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 159, 105795
Points to consider for revising the ICH S7A guideline on safety and secondary pharmacology
- 6 March 2025
- Published by Elsevier in Regulatory Toxicology and Pharmacology
- Vol. 159, 105795
Points to consider for revising the ICH S7A guideline on safety and secondary pharmacology
- Open Access
- 11 December 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (12) , e70098
An overview of drug‐induced sodium channel blockade and changes in cardiac conduction: Implications for drug safety
The human voltage‐gated sodium channel Nav1.5 (hNav1.5/SCN5A) plays a critical role in the initiation and propagation of action potentials in cardiac myocytes, and its modulation by various drugs has significant implications for cardiac safety. Drug‐dependent block of Nav1.5 current (INa) can lead to significant alterations in cardiac electrophysiology, potentially resulting in conduction slowing and an increased risk of proarrhythmic events. This review aims to provide a comprehensive overview of the mechanisms by which various pharmacological agents interact with Nav1.5, focusing on the molecular determinants of drug binding and the resultant electrophysiological effects. We discuss the structural features of Nav1.5 that influence drug affinity and specificity. Special attention is given to the concept of state‐dependent block, where drug binding is influenced by the conformational state of the channel, and its relevance to therapeutic efficacy and safety. The review also examines the clinical implications of INa block, highlighting case studies of drugs that have been associated with adverse cardiac events, and how the Vaughan‐Williams Classification system has been employed to qualify “unsafe” sodium channel block. Furthermore, we explore the methodologies currently used to assess INa block in nonclinical and clinical settings, with the hope of providing a weight of evidence approach including in silico modeling, in vitro electrophysiological assays and in vivo cardiac safety studies for mitigating proarrhythmic risk early in drug discovery. This review underscores the importance of understanding Nav1.5 pharmacology in the context of drug development and cardiac risk assessment.
- 11 December 2024
- Published by Wiley in Clinical and Translational Science
- Vol. 17 (12) , e70098
Open AccessAn overview of drug‐induced sodium channel blockade and changes in cardiac conduction: Implications for drug safety
The human voltage‐gated sodium channel Nav1.5 (hNav1.5/SCN5A) plays a critical role in the initiation and propagation of action potentials in cardiac myocytes, and its modulation by various drugs has significant implications for cardiac safety. Drug‐dependent block of Nav1.5 current (INa) can lead to significant alterations in cardiac electrophysiology, potentially resulting in conduction slowing and an increased risk of proarrhythmic events. This review aims to provide a comprehensive overview of the mechanisms by which various pharmacological agents interact with Nav1.5, focusing on the molecular determinants of drug binding and the resultant electrophysiological effects. We discuss the structural features of Nav1.5 that influence drug affinity and specificity. Special attention is given to the concept of state‐dependent block, where drug binding is influenced by the conformational state of the channel, and its relevance to therapeutic efficacy and safety. The review also examines the clinical implications of INa block, highlighting case studies of drugs that have been associated with adverse cardiac events, and how the Vaughan‐Williams Classification system has been employed to qualify “unsafe” sodium channel block. Furthermore, we explore the methodologies currently used to assess INa block in nonclinical and clinical settings, with the hope of providing a weight of evidence approach including in silico modeling, in vitro electrophysiological assays and in vivo cardiac safety studies for mitigating proarrhythmic risk early in drug discovery. This review underscores the importance of understanding Nav1.5 pharmacology in the context of drug development and cardiac risk assessment.